Antimicrobial Peptide LL-37 and IDR-1 Ameliorate MRSA Pneumonia in Vivo | Zendy

Man Hou | Zendy; Nengwei Zhang | Zendy; H. J. Yang | Zendy; Xiangyu Meng | Zendy; Yang Ruan | Zendy; Laigeng Li | Zendy; Tieying Sun | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antimicrobial Peptide LL-37 and IDR-1 Ameliorate MRSA Pneumonia <b><i>in Vivo</i></b>

Author(s) -

Man Hou,

Nengwei Zhang,

H. J. Yang,

Xiangyu Meng,

Yang Ruan,

Laigeng Li,

Tieying Sun

Publication year - 2013

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000354465

Subject(s) - in vivo , cathelicidin , bronchoalveolar lavage , medicine , pneumonia , antimicrobial , staphylococcus aureus , antimicrobial peptides , pharmacology , western blot , immunology , microbiology and biotechnology , chemistry , lung , biology , biochemistry , genetics , bacteria , gene

The only human cathelicidin, LL-37, and the innate defense regulator peptide IDR-1, which have been proven to have antimicrobial activity, represent essential elements of immunity. Our previous study showed that the peptide LL-37 was protective in vitro to attenuate LTA-induced inflammatory effects. Methicillin-resistant staphylococcus aureus (MRSA) causes a multitude of serious and sometimes life-threatening diseases around the globe. However, the effect of LL-37 and IDR-1 in MRSA-induced pneumonia is unknown. In the present study, we explored the potential of LL-37 and IDR-1 in ameliorating MRSA-induced pneumonia in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research